Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for Levorphanol Tartrate by Acertis Pharmaceuticals

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:31:22 AM

Assessment confidence: 89% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Levorphanol Tartrate by Acertis Pharmaceuticals is significant as it positions Acertis to strengthen its foothold in the competitive opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from other manufacturers. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from other opioid manufacturers. The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 0 competitive items passed relevance filtering for Acertis Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance Acertis' position in the pain management market, particularly in the opioid segment, where competition is intense..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVORPHANOL TARTRATE (SUPPL) (FDA). Sub-indication match (rare disease); Entity match (levorphanol tartrate). The acceptance of this application indicates a positive regulatory trajectory, but further monitoring is required to understand the implications for market entry and compliance.

Key Risks

Elevated medium regulatory exposure for Acertis Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Acertis in the opioid segment, impacting revenue streams and competitive positioning against established players.
Portfolio teams should assess the potential market impact and prepare for competitive responses from other opioid manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for approval and any subsequent market entry strategies from Acertis.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Human Experimental Models of Pain (HEMP)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Acertis Pharmaceuticals
Levorphanol Tartrate
pain management sector

Commercial impact

medium

The approval could lead to increased market share for Acertis in the opioid segment, impacting revenue streams and competitive positioning against established players.

Regulatory impact

medium

The acceptance of this application indicates a positive regulatory trajectory, but further monitoring is required to understand the implications for market entry and compliance.

What to watch

Monitor the timeline for approval and any subsequent market entry strategies from Acertis.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.